S. Baldwin

发表

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

R. Coler, S. Reed, D. Carter, 2017, Scientific Reports.

Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae

J. Lamb, I. Orme, D. Young, 1997, Infection and immunity.

Clinical vaccine development for H5N1 influenza

C. Clegg, S. Baldwin, J. Rininger, 2013, Expert review of vaccines.

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy

R. Coler, S. Reed, T. Vedvick, 2012, Influenza and other respiratory viruses.

Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.

I. Orme, J. Ulmer, D. Montgomery, 1999, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines

S. Bertholet, R. Coler, S. Reed, 2010, PloS one.

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

Magdalini Moutaftsi, S. Bertholet, R. Coler, 2011, PloS one.

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases

R. Coler, D. Ordway, S. Baldwin, 2019, PLoS neglected tropical diseases.

Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

R. Coler, S. Reed, Alex F Picone, 2011, Journal of immunological methods.

Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults

R. Coler, S. Baldwin, J. McElhaney, 2013, Expert review of vaccines.

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model

R. Coler, S. Reed, Sang-Nae Cho, 2019, Scientific Reports.

Evaluation of New Vaccines in the Mouse and Guinea Pig Model of Tuberculosis

Alan D. Roberts, I. Orme, J. Ulmer, 1998, Infection and Immunity.

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

S. Bertholet, R. Coler, S. Reed, 2013, The Journal of infectious diseases.

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant

T. Vedvick, C. Coman, M. O'Hara, 2016, Human vaccines & immunotherapeutics.

Mycobacterium abscessus: It’s Complex

R. Coler, E. Chan, S. Baldwin, 2022, Microorganisms.

Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.

James D. Allen, R. Coler, S. Reed, 2017, Vaccine.

Biotherapy: A New Dimension in Cancer Treatment

S. Baldwin, C. McCall, L. Weimer, 1989, Bio/Technology.

Immunomodulatory and Physical Effects of Phospholipid Composition in Vaccine Adjuvant Emulsions

S. Reed, T. Vedvick, C. Fox, 2012, AAPS PharmSciTech.

Innovations in emulsion technology

S. Reed, D. Carter, C. Fox, 2012 .

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

S. Reed, T. Vedvick, C. Fox, 2011, Vaccine.

Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines

S. Reed, T. Vedvick, E. Angov, 2012, Clinical and Vaccine Immunology.

Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses.

S. Reed, D. Carter, N. Van Hoeven, 2013, BioTechniques.

Antigen presentation by B cells guides programing of memory CD4+ T‐cell responses to a TLR4‐agonist containing vaccine in mice

R. Coler, M. T. Orr, S. Baldwin, 2016, European journal of immunology.

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations

R. Coler, S. Reed, B. Podell, 2022, Frontiers in Microbiology.

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

S. Bertholet, R. Coler, S. Reed, 2012, The Journal of Immunology.

the Development of a Tuberculosis Vaccine The Importance of Adjuvant Formulation in

S. Bertholet, R. Coler, S. Reed, 2012 .

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Y. Goto, S. Bertholet, R. Coler, 2009, Vaccine.

Bertholet Mycobacterium tuberculosis Against Multidrug-Resistant A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects

G. Ireton, S. Bertholet, R. Coler, 2010 .

Adjuvant solution for pandemic influenza vaccine production

Lucy A. Perrone, S. Reed, C. Clegg, 2012, Proceedings of the National Academy of Sciences.

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

R. Coler, S. Reed, C. Fox, 2021, PloS one.

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.

R. Coler, S. Reed, M. Pallansch, 2011, Vaccine.

The ID93 Tuberculosis Vaccine Candidate Does Not Induce Sensitivity to Purified Protein Derivative

G. Ireton, R. Coler, S. Reed, 2014, Clinical and Vaccine Immunology.

Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29

R. Coler, W. Finlay, G. Hatfull, 2019, Antimicrobial Agents and Chemotherapy.

Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen.

R. Coler, S. Reed, A. Khandhar, 2022, Tuberculosis.

Transient and stable transfection of Chinese hamster ovary cells with the recombinant feline erythropoietin gene and expression, purification, and biological activity of feline erythropoietin protein.

S. Baldwin, M. Mcdermott, S. Hunter, 2003, American journal of veterinary research.

The biological effects of five feline IFN-α subtypes

J. Cohen, S. Baldwin, K. Sellins, 2004 .

Influence of increased age on the development of herpes stromal keratitis

C. Wilcox, I. Orme, J. Turner, 2003, Experimental Gerontology.

A membrane vesicle/ribosome preparation fromSerratia marcescens elicits peritoneal exudate cells expressing both tumoricidal and bactericidal activity

D. Riches, P. Campbell, S. Baldwin, 1992, Inflammation.

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Christopher B Fox, Tony Phan, R. Coler, 2013, Journal of controlled release : official journal of the Controlled Release Society.

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

Sylvie Bertholet, Tony Phan, G. Ireton, 2010, Science Translational Medicine.

Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis1

G. Ireton, S. Bertholet, R. Coler, 2008, The Journal of Immunology.

The adjuvant GLA-AF enhances human intradermal vaccine responses

S. Reed, D. Carter, A. Magill, 2018, Science Advances.

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity

R. Coler, S. Baldwin, S. E. Larsen, 2022, Frontiers in Immunology.

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

G. Ireton, S. Bertholet, R. Coler, 2009, Vaccine.

Immunogenicity and protective efficacy of a tuberculosis DNA vaccine

Donna L. Montgomery, Olivier Denis, I. Orme, 1996, Nature Medicine.

Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.

S. Reed, M. Christiansen, D. Carter, 2016, Vaccine.

Cloning, expression, purification, and biological activity of five feline type I interferons.

E. Best, S. Baldwin, S. Snyder, 2002, Veterinary immunology and immunopathology.

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection

R. Coler, S. Reed, N. Van Hoeven, 2018, Front. Immunol..

Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity.

R. Coler, D. Carter, M. Blackman, 2020, Vaccine.

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations

D. E. Parks, D. Clements, R. Coler, 2016, PloS one.

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate

R. Coler, S. Reed, B. Podell, 2015, Clinical and Vaccine Immunology.

Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

G. Ireton, R. Coler, S. Reed, 2013, Vaccine.

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples

R. Coler, L. Carter, N. King, 2021, Journal of Immunological Methods.

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples

R. Coler, L. Carter, N. King, 2021, bioRxiv.

Protection against Tuberculosis with Homologous or Heterologous Protein/Vector Vaccine Approaches Is Not Dependent on CD8+ T Cells

Magdalini Moutaftsi, S. Bertholet, R. Coler, 2013, The Journal of Immunology.

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models

R. Coler, B. Podell, D. Ordway, 2021, Scientific Reports.

Vaccines Against Mycobacterium tuberculosis: An Overview from Preclinical Animal Studies to the Clinic

R. Coler, S. Reed, S. Baldwin, 2012 .

Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

G. Ireton, R. Coler, S. Reed, 2014, Tuberculosis.

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis

R. Coler, S. Reed, S. Baldwin, 2023, Vaccines.

RNA-based vaccine demonstrates prophylactic efficacy against Mycobacterium tuberculosis challenge in a mouse model

R. Coler, S. Reed, S. Baldwin, 2022, bioRxiv.

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment

R. Coler, B. Podell, B. Granger, 2018, Vaccines.

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?

R. Coler, S. Baldwin, S. E. Larsen, 2023, International Journal of Infectious Diseases.

SARS-CoV-2 infection and immune responses

R. Coler, S. Baldwin, Rakhi Harne, 2023, AIMS microbiology.

Subunit vaccine candidate with adjuvant confers protection against clinical Mycobacterium avium in wild type and immunocompromised mouse models

R. Coler, T. Parish, S. Baldwin, 2019, The Journal of Immunology.

Immunomodulatory and Physical Effects of Phospholipid Composition in Vaccine Adjuvant Emulsions

S. Reed, T. Vedvick, C. Fox, 2012, AAPS PharmSciTech.

Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event

R. Coler, T. Parish, Matthew B. McNeil, 2022, Tuberculosis.

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

R. Coler, S. Reed, Sang-Nae Cho, 2023, Infectious Diseases and Therapy.

Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration

R. Coler, A. Hickey, I. Stewart, 2023, Pharmaceuticals.

Mycobacterium tuberculosis the Development of Vaccines against Identification of Human T Cell Antigens for

G. Ireton, S. Reed, T. Vedvick, 2013 .

This information is current as Mycobacterium tuberculosis the Development of Vaccines against Identification of Human T Cell Antigens for Coler

G. Ireton, S. Bertholet, R. Coler, 2008 .